Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Heart. 2023 Mar 27;109(8):619-625. doi: 10.1136/heartjnl-2022-321435.
Fontan-associated liver disease (FALD) is universal post-Fontan palliation; however, its impact on survival remains controversial and current diagnostic tools have limitations. We aimed to assess the prognostic role of liver fibrosis scores (aminotransferase to platelet ratio [APRI] and fibrosis-4 [FIB-4]) and their association with haemodynamics and other markers of liver disease.
159 adults (age ≥18 years) post-Fontan undergoing catheterisation at Mayo Clinic, Minnesota, between 1999 and 2017 were included. Invasive haemodynamics and FALD-related laboratory, imaging and pathology data were documented.
Mean age was 31.5±9.3 years, while median age at Fontan procedure was 7.5 years (4-14). Median APRI score (n=159) was 0.49 (0.33-0.61) and median FIB-4 score (n=94) was 1.12 (0.71-1.65). Correlations between APRI and FIB-4 scores and Fontan pressures (r=0.30, p=0.0002; r=0.34, p=0.0008, respectively) and pulmonary arterial wedge pressure (r=0.25, p=0.002; r=0.30, p=0.005, respectively) were weak. Median average hepatic stiffness by magnetic resonance elastography was 4.9 kPa (4.3-6.0; n=26) and 24 (77.4%) showed stage 3 or 4 liver fibrosis on biopsy; these variables were not associated with APRI/FIB-4 scores. On multivariable analyses, APRI and FIB-4 scores were independently associated with overall mortality (HR 1.31 [1.07-1.55] per unit increase, p=0.003; HR 2.15 [1.31-3.54] per unit increase, p=0.003, respectively).
APRI and FIB-4 scores were associated with long-term all-cause mortality in Fontan patients independent of other prognostic markers. Correlations between haemodynamic status and liver scores were weak; furthermore, most markers of liver fibrosis failed to correlate with non-invasive indices, underscoring the complexity of FALD.
Fontan 相关肝疾病(FALD)是 Fontan 后普遍存在的疾病;然而,其对生存率的影响仍存在争议,且目前的诊断工具存在局限性。我们旨在评估肝纤维化评分(天冬氨酸转氨酶与血小板比值[APRI]和纤维化-4[FIB-4])的预后作用及其与血液动力学和其他肝病标志物的相关性。
1999 年至 2017 年间,明尼苏达州梅奥诊所对 159 例接受 Fontan 治疗后年龄≥18 岁的成年人进行了导管插入术。记录了侵入性血液动力学和 FALD 相关的实验室、影像学和病理学数据。
平均年龄为 31.5±9.3 岁,而 Fontan 手术时的中位年龄为 7.5 岁(4-14 岁)。159 例患者的中位 APRI 评分(n=159)为 0.49(0.33-0.61),94 例患者的中位 FIB-4 评分为 1.12(0.71-1.65)。APRI 和 FIB-4 评分与 Fontan 压力(r=0.30,p=0.0002;r=0.34,p=0.0008)和肺动脉楔压(r=0.25,p=0.002;r=0.30,p=0.005)之间的相关性较弱。磁共振弹性成像测量的平均肝硬度中位数为 4.9kPa(4.3-6.0;n=26),24 例(77.4%)肝活检显示 3 或 4 期肝纤维化;这些变量与 APRI/FIB-4 评分无关。多变量分析显示,APRI 和 FIB-4 评分与总体死亡率独立相关(每增加 1 单位,HR 为 1.31[1.07-1.55],p=0.003;每增加 1 单位,HR 为 2.15[1.31-3.54],p=0.003)。
APRI 和 FIB-4 评分与 Fontan 患者的长期全因死亡率相关,独立于其他预后标志物。血液动力学状态与肝评分之间的相关性较弱;此外,大多数肝纤维化标志物与非侵入性指数不相关,这突显了 FALD 的复杂性。